MEDI0562, an agonist of OX40, was safely administered to patients with advanced solid tumors (47% HNSCC) in a phase I dose-escalation study (NCT02318394) at doses up to 10 mg/kg (Glisson et al., 2020). Here, TNFRSF4 is linked to head and neck squamous cell carcinoma.